303 In the index

LGD-2226 LGD-2226

An early experimental muscle-building compound studied only in animals, aimed at building bone and muscle with fewer prostate side effects than testosterone. It was never tested in humans, so nothing is known about its real-world effects or safety in people.

Also known as LGD2226

Effects Build muscle

Routes Oral

Legal status Research chemical

WADA Banned at all times

3D Molecular Structure of C₁₄H₉F₉N₂O

Drag to rotate · scroll to zoom

Chemistry

Formula: C14H9F9N2O
Molar mass: 392.22
CAS: 328947-93-9
PubChem CID: 11560224

Reported dosing

Limited data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established (development discontinued)

Reported range Early preclinical/Phase I doses not widely published

Route Oral

Frequency Not established

Duration Not established

An early Ligand Pharmaceuticals SARM candidate that never advanced past early development; essentially no human dosing data exists.

Where this comes from Early-stage/preclinical pharma data only

Human data for this compound is limited. Read the figures above as a record of reported use rather than established dosing.